Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Using ExpreS 2 ion’s ExpreS2 platform, the company will manufacture the antigen constructs obtained from RAVEN. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.
Let's personalize your content